3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
10
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Hyperglycemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Breast Neoplasms
1
Interventions
Trastuzumab
242
Paclitaxel
223
Fulvestrant
196
Capecitabine
182
Docetaxel
164
Letrozole
142
pembrolizumab
115
Carboplatin
100
exemestane
98
Gemcitabine
98
Cyclophosphamide
92
palbociclib
86
Anastrozole
83
pertuzumab
78
Lapatinib
73
Bevacizumab
71
ribociclib
68
130-nm albumin-bound paclitaxel
66
abemaciclib
59
eribulin
58
Doxorubicin
55
Vinorelbine
51
Injections
47
Ado-Trastuzumab Emtansine
47
Tamoxifen
45
Everolimus
44
Albumin-Bound Paclitaxel
44
atezolizumab
35
trastuzumab deruxtecan
34
Nivolumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
dapagliflozin
×
Breast
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts